TPST — Tempest Therapeutics Balance Sheet
0.000.00%
- $15.37m
- $7.86m
- 30
- 14
- 30
- 13
Annual balance sheet for Tempest Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 38.2 | 51.8 | 31.2 | 39.2 | 30.3 |
| Net Total Receivables | 0.314 | — | — | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 40.9 | 69 | 33 | 40.4 | 31.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.16 | 4.16 | 12.7 | 10.8 | 9.53 |
| Other Long Term Assets | |||||
| Total Assets | 43.4 | 73.2 | 46.1 | 51.6 | 41.5 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.99 | 20 | 7.28 | 9.41 | 14.2 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 10.4 | 37.1 | 28 | 24.8 | 22.4 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 33.1 | 36.1 | 18.1 | 26.8 | 19.1 |
| Total Liabilities & Shareholders' Equity | 43.4 | 73.2 | 46.1 | 51.6 | 41.5 |
| Total Common Shares Outstanding |